Abstract: A method of repairing a meniscal tear of a subject includes providing a sheet of collagen membrane material having on one side thereof a smooth barrier face which inhibits cell adhesion thereon and inhibits passage of cells therethrough. The sheet has a fibrous face opposite the smooth barrier face, the fibrous face allowing cell growth thereon. The collagen is predominantly collagen I. The sheet of collagen membrane material is fixed over a meniscal tear so that the fibrous face is oriented toward the meniscal tear.

Abstract: A method of repairing a meniscal tear of a subject includes providing a sheet of collagen membrane material having on one side thereof a smooth barrier face which inhibits cell adhesion thereon and inhibits passage of cells therethrough. The sheet has a fibrous face opposite the smooth barrier face, the fibrous face allowing cell growth thereon. The collagen is predominantly collagen I. The sheet of collagen membrane material is fixed over a meniscal tear so that the fibrous face is oriented toward the meniscal tear.

Abstract: A compound selected from the group consisting of all possible isomers or racemates of a compound of the formula wherein the various substituents are as defined in the specification and its non-toxic, pharmaceutically acceptable salts with acids or bases having anti-anoxic, anti-ischemic and neuronal protective anti-depressant activities.

Abstract: A compound selected from the group consisting of all possible isomers or racemates of a compound of the formula 1

Abstract: A compound selected from the group consisting of enantiomers and diastereoisomer forms and mixtures thereof of the formula wherein the substituents are defined as in the application having a strong affinity for optical receptors, central analgesic, diuretic, anti-arrythmic, hypotensive and cerebral anti-ischemic activity.

Abstract: A method of producing a microencapsulated pharmaceutical formulation is disclosed comprising causing a dye to be attached to the surface of pharmaceutical particles or particle clusters and applying a source of radiant energy to the dye in the presence of a liquid polymeric or polymerisable material so as to cause the material to cross-link, producing a conformal layer of cross-linked polymer on the particulate surfaces. Preferably, the polymer provides an immuno-protective layer around the particles, while allowing therapeutic components to exit the microcapsules. Microencapsulated pharmaceutical formulations and their medical use are also disclosed, especially for the treatment of diabetes by encapsulating insulin secreting cells.

Abstract: Compounds of the formula ##STR1## in all possible racemic, enantiomeric and diastereoisomeric forms and their non-toxic, pharmaceutically acceptable salts with acids and bases having antagonistic properties for angiotensin II receptors and a process and novel intermediates for their properties.

Abstract: Compounds of the formula ##STR1## in all possible racemic, enantiomeric and diastereoisomeric forms and their non-toxic, pharmaceutically acceptable salts with acids and bases having antagonistic properties for angiotensin II receptors and a process and novel intermediates for their properties.

Abstract: Novel bicyclic compounds in all possible racemic, enantiomeric and diasteroisomeric forms of the formula ##STR1## having antagonistic properties for angiotensin II receptors and novel intermediates and process for their preparation.

Abstract: Novel indanes in all possible stereoisomer forms of the formula ##STR1## wherein the substituents are as defined in the specification and their non-toxic, pharmaceutically acceptable acid addition salts and their hydrates having central analgesic properties as well as antiarrhythmic and diuretic activities.

Abstract: A compound in all racemic or optionally active forms selected from the group consisting of a compound of the formula ##STR1## where the substituents are defined as in the specification and their non-toxic, pharmaceutically acceptable acid addition salts having anti-anoxic activity and a novel process and intermediates for their preparation.

Abstract: A compound selected from the group consisting of all possible racemic, enantiomeric and diastereoisomeric forms of a compound of the formula ##STR1## wherein E and G together form a group selected from the group: ##STR2## wherein A, R, R.sub.1, R.sub.2 and Y are as defined in the specification.

Abstract: Novel indole-carboxamides of the formula ##STR1## and their non-toxic pharmaceutically acceptable acid addition salts having remarkable anti-arrhytmic properties.

Abstract: A compound selected from the group consisting of all possible racemic, enantiomeric and diastereoisomeric forms of a compound of the formula ##STR1## wherein E and G together form a group selected from the group: ##STR2## consisting of a) ##STR3## wherein, A is a cycloalkyl of 3-6 carbon optionally substituted, R, R.sub.1, R.sub.2 and Y are defined in the specification.

Abstract: Novel indanes in all possible stereoisomer forms of the formula ##STR1## wherein the substrates are as defined in the application and their non-toxic, pharmaceutically acceptable acid addition salts and their hydrates are disclosed as having central analgesic properties as well as antiarrhythmic and diuretic activities.

Abstract: A compound and all possible racemic or optically active isomer forms, selected from the group consisting of compound of the formula ##STR1## wherein the substituents are defined as set forth in the application as filed. Useful for treating cerebral insufficiencies of anoxic or ischemic origin.

Abstract: Novel bicyclic compounds in all possible racemic, enantiomeric and diasteroisomeric forms of the formula ##STR1## having antagonistic properties for angiotensin II receptors and novel intermediates and process for their preparation.

Abstract: A novel process for the preparation of 4H-1,2,4-triazoles in their racemic or optically active forms of the formula ##STR1## wherein the compounds have analgesic activity.

Abstract: A compound selected from the group consisting of racemates, enantiomeric and diastereoisomeric forms of a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms optionally substituted with at least one halogen, hydroxy, alkyl or alkoxy of 1 to 4 carbon atoms or taken together with the nitrogen to which they are attached form a heterocycle optionally containing a heteroatom selected from the group consisting of --O--, --S-- and nitrogen optionally substituted with alkyl or alkoxy of 1 to 5 carbon atoms, optionally substituted benzyl and phenyl, R.sub.3 and R.sub.4 are individually selected from the group consisting of hydrogen, halogen, hydroxy and alkyl and alkoxy of 1 to 5 carbon atoms optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxy, phenyl and alkyl and alkoxy of 1 to 4 carbon atoms, R.sub.

Abstract: A compound selected from the group consisting of enantiomers and diastereoisomer forms and mixtures thereof of the formula ##STR1## wherein R.sub.6 is selected from the group consisting of hydrogen, halogen and alkyl and alkoxy of 1 to 5 carbon atoms, R.sub.1 and R.sub.2 are individually hydrogen or alkyl of 1 to 5 carbon atoms or taken together with the carbon atoms to which they are attached form a cycloalkyl of 3 to 6 carbon atoms optionally containing a heteroatom selected from the group consisting of --S--, --O-- and --N--, one of A and B has the formula ##STR2## and the other has the formula ##STR3## R is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms, Z is selected from the group consisting of --(CH.sub.2).sub.n --, branched alkylene of 2 to 8 carbon atoms and --CH.sub.2 O--, n is an integer of 0 to 5, X, X' and X" are individually selected from the group consisting of hydrogen, alkyl and alkoxy of 1 to 4 carbon atoms, halogen, --OH, --CF.sub.3, --NO.sub.2, --NH.sub.